[1]

Isaac A, Dalili D, Daniel D, et al. State-of-the-art imaging for diagnosis of metastatic bone disease[J/OL]. Der Radiologe, 2020[2020-03-24]. https://link.springer.com/article/10.1007/s00117-020-00666-6. [published online ahead of print March 24, 2020]. DOI: 10.1007/s00117−020−00666−6.
[2]

Weller D, Bamias, A. Bone health in cancer patients–An important clinical issue[J/OL]. Eur J Cancer Care (Engl), 2017, 26(6): e12791[2019-01-28]. https://onlinelibrary.wiley.com/doi/full/10.1111/ecc.12791. DOI: 10.1111/ecc.12791.
[3]

WHO. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents[EB/OL]. (2019-01)[2019-01-28]. https://www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en/.
[4] Goyal J, Antonarakis ES.  Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases[J]. Cancer Lett, 2012, 323(2): 135-146.   doi: 10.1016/j.canlet.2012.04.001
[5] Hojjat A, Markus E, Kambiz R, et al.  Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning[J]. PET Clin, 2018, 13(4): 491-503.   doi: 10.1016/j.cpet.2018.05.005
[6]

Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain[J/OL]. Cochrane Database Syst Rev, 2011, 6(7): CD003347[2019-01-28]. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003347.pub2/full. DOI: 10.1002/14651858.CD003347.pub2.
[7]

匡安仁, 李林. 核医学[M]. 2版. 北京: 高等教育出版社, 2017: 266−271.

Kuang AR, Li L. Nuclear medicine[M]. 2nd ed. Beijing: Higher Education Press, 2017: 266−271.
[8]

Heianna J, Miyauchi T, Endo WM, et al. Tumor regression of multiple bone metastases from breast cancer after administration of strontium-89 chloride (Metastron)[J/OL]. Acta Radiol Short Rep, 2014, 3(4): 2047981613493412[2019-01-28]. https://journals.sagepub.com/doi/10.1177/2047981613493412. DOI: 10.1177/2047981613493412.
[9] 中华医学会核医学分会转移性骨肿瘤治疗工作委员会.  氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017年版)[J]. 中华核医学与分子影像杂志, 2018, 38(6): 412-415.   doi: 10.3760/cma.j.issn.2095-2848.2018.06.008
The Chinese Society of Nuclear Medicine Working Committee for Treatment of Bone Metastasis.  Expert consensus on strontium-89 chloride treatment of bone metastases (2017)[J]. Chin J Nucl Med Mol Imaging, 2018, 38(6): 412-415.   doi: 10.3760/cma.j.issn.2095-2848.2018.06.008
[10] 耿向群.  89-锶治疗肺癌骨转移的临床疗效分析[J]. 中国医学创新, 2013, 10(33): 21-22.   doi: 10.3969/j.issn.1674-4985.2013.33.010
Geng XQ.  Clinical Analysis of 89-SR Treatment on Bone Metastasis on Lung Cancer[J]. Med Inn China, 2013, 10(33): 21-22.   doi: 10.3969/j.issn.1674-4985.2013.33.010
[11] 范义湘, 罗荣城, 李贵平, 等.  89Sr治疗肺癌骨转移疼痛65例疗效分析[J]. 中国临床康复, 2004, 8(5): 812-813.   doi: 10.3321/j.issn:1673-8225.2004.05.007
Fan YX, Luo RC, Li GP, et al.  Antalgic effects of strontium-89 therapy on bone metastases in 65 patients with lung cancer[J]. Chin J Clin Rehabil, 2004, 8(5): 812-813.   doi: 10.3321/j.issn:1673-8225.2004.05.007
[12] 郑航, 罗荣城, 范义湘.  89SrCl2治疗肺癌骨转移126例疗效分析[J]. 第一军医大学学报, 2004, 24(10): 1194-1196.   doi: 10.3321/j.issn:1673-4254.2004.10.028
Zheng H, Luo RC, Fan YX.  Therapeutic effects of 89SrCl2 against osseous metastases of lung cancer: analysis of 126 cases[J]. J First Mil Med Univ, 2004, 24(10): 1194-1196.   doi: 10.3321/j.issn:1673-4254.2004.10.028
[13] 胥杰, 陈晓.  89Sr治疗30例肺癌多发骨转移的疗效观察[J]. 中国呼吸与危重监护杂志, 2008, 7(2): 104-106.   doi: 10.3969/j.issn.1671-6205.2008.02.006
Xu J, Chen X.  Therapeutic effects of strontium-89 to prevent bone metastases of lung cancer: A clinical analysis of 30 cases[J]. Chin J Respir Crit Care Med, 2008, 7(2): 104-106.   doi: 10.3969/j.issn.1671-6205.2008.02.006
[14] D' Antonio C, Passaro A, Gori B, et al.  Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies[J]. Ther Adv Med Oncol, 2014, 6(3): 101-114.   doi: 10.1177/1758834014521110
[15] Lange R, Ter Heine R, Knapp RF, et al.  Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases[J]. Bone, 2016, 91: 159-179.   doi: 10.1016/j.bone.2016.08.002
[16] 李宁, 杨志, 柴华, 等.  唑来膦酸联合89Sr治疗无症状非小细胞肺癌骨转移临床研究[J]. 中华肿瘤防治杂志, 2018, 25(13): 962-967.   doi: 10.16073/j.cnki.cjcpt.2018.13.009
Li N, Yang Z, Chai H, et al.  Clinical research of zoledronic acid and strontium-89 in treatment of patients with asymptomatic bone metastases from non-small cell lung cancer[J]. Chin J Cancer Prev Treat, 2018, 25(13): 962-967.   doi: 10.16073/j.cnki.cjcpt.2018.13.009
[17] 李梅, 王火强.  89SrCl2联合伊班膦酸钠对肺癌骨转移骨痛的疗效分析[J]. 放射免疫学杂志, 2013, 26(4): 390-392.   doi: 10.3969/j.issn.1008-9810.2013.04.003
Li M, Wang HQ.  Therapeutic efficacy of 89SrCl2 combined with ibandronate in the treatment of osseous metastasis of lung cancer[J]. J Radioimmunol, 2013, 26(4): 390-392.   doi: 10.3969/j.issn.1008-9810.2013.04.003
[18] 梁忠, 于珺, 李雨林.  89锶和博宁治疗非小细胞肺癌骨转移87例疗效观察[J]. 第四军医大学学报, 2007, 28(19): 1737-.   doi: 10.3321/j.issn:1000-2790.2007.19.031
Liang Z, Yu J, Li YL.  Clinical observation of 87 cases of bone metastasis from non-small cell lung cancer treated with strontium-89 and bonin[J]. J Fourth Mil Med Univ, 2007, 28(19): 1737-.   doi: 10.3321/j.issn:1000-2790.2007.19.031
[19] 董占飞, 秦永德, 王新华.  89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察[J]. 中国肿瘤临床, 2012, 39(21): 1660-1662.   doi: 10.3969/j.issn.1000-8179.2012.21.024
Dong ZF, Qin YD, Wang XH.  Clinical observation of internal radiotherapy using 89Sr 99Tc-MDP and Zoledronic acid in the treatment and pain relief of lung cancer patients with bone metastasis[J]. Chin J Clin Oncol, 2012, 39(21): 1660-1662.   doi: 10.3969/j.issn.1000-8179.2012.21.024
[20] 苏瑾, 尤长宣, 蔡绍曦, 等.  89SrCl2和/或骨膦治疗肺癌骨转移疗效分析[J]. 中国肺癌杂志, 2002, 5(5): 357-359.   doi: 10.3779/j.issn.1009-3419.2002.05.11
Su J, You CX, Cai SX, et al.  89SrCl2 and/Or Bonefos in the treatment of bone metastasis from pulmonary carcinoma[J]. Chin J Lung Cancer, 2002, 5(5): 357-359.   doi: 10.3779/j.issn.1009-3419.2002.05.11
[21] 邵珊珊, 李鹏, 张良明.  锶89与放疗在非小细胞肺癌骨转移骨痛治疗中的疗效比较[J]. 中国医药科学, 2014, 4(5): 22-24.
Shao SS, Li P, Zhang LM.  A comparison of curative effects of Strontium 89 and radiotherapy in the treatment of bone metastasis and ostealgia induced by non-small cell lung cancer[J]. China Med Pharm, 2014, 4(5): 22-24.
[22] 张云平, 江敏霞, 蔡奋, 等.  89锶联合鲑鱼降钙素治疗肺癌骨转移骨痛的疗效观察[J]. 汕头大学医学院学报, 2016, 29(3): 148-149.   doi: 10.13401/j.cnki.jsumc.2016.03.008
Zhang YP, Jiang MX, Cai F, et al.  Clinical observation of 89Sr combined with salmon calcitonin in the treatment of bone metastasis and pain of lung cancer[J]. J Shantou Univ Med Coll, 2016, 29(3): 148-149.   doi: 10.13401/j.cnki.jsumc.2016.03.008
[23] 刘江, 赵颖如, 徐文贵.  放射性核素钐153的应用进展[J]. 国际医学放射学杂志, 2014, 37(4): 366-370.   doi: 10.3874/j.issn.1674-1897.2014.04.Z0412
Liu J, Zhao YR, Xu WG.  Application progress of radionuclide Samarium-153[J]. Int J Med Radiol, 2014, 37(4): 366-370.   doi: 10.3874/j.issn.1674-1897.2014.04.Z0412
[24] Farhanghi M, Holmes RA, Volkert WA, et al.  Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer[J]. J Nucl Med, 1992, 33(8): 1451-1458.
[25] Guerra Liberal FDC, Tavares AAS, Tavares JMRS.  Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153[J]. Appl Radiat Isot, 2016, 110: 87-99.   doi: 10.1016/j.apradiso.2016.01.003
[26] Ratsimanohatra H, Barlesi F, Doddoli C, et al.  Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer[J]. Rev Mal Respir, 2005, 22(2): 317-320.   doi: 10.1016/S0761-8425(05)85484-1
[27] 王水利, 吴桦, 王勇文, 等.  153Sm-EDTMP对肺癌并骨转移治疗价值的探讨[J]. 中国现代医学杂志, 2002, 12(2): 92-93.   doi: 10.3969/j.issn.1005-8982.2002.02.044
Wang SL, Wu H, Wang YW, et al.  Discussion of 153Sm-EDTMP in the treatment of lung cancer complicated with bone metastases[J]. China J Mod Med, 2002, 12(2): 92-93.   doi: 10.3969/j.issn.1005-8982.2002.02.044
[28] 舒斌, 徐蓉生, 段云, 等.  153Sm-EDTMP对小细胞肺癌与非小细胞肺癌骨转移的止痛疗效观察[J]. 华西医学, 2004, 19(2): 201-202.   doi: 10.3969/j.issn.1002-0179.2004.02.015
Shu B, Xu RS, Duan Y, et al.  Clinical observation of 153Sm-EDTMP as a palliative treatment for small cell lung cancer and non-small cell lung cancer patient with painful bone metastasis[J]. West China Med J, 2004, 19(2): 201-202.   doi: 10.3969/j.issn.1002-0179.2004.02.015
[29] Montesano T, Giacomobono S, Acqualagna G, et al.  Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study[J]. Clin Ter, 2009, 160(3): 193-199.
[30] 李少民, 王永亮, 李淳成.  核素、博宁及化疗治疗骨转移疼痛疗效分析[J]. 肿瘤研究与临床, 1999, 11(1): 45-46.
Li SM, Wang YL, Li CC.  Therapeutic effect of radionuclide, Bonin and chemotherapy on bone metastasis pain[J]. Cancer Res Clin, 1999, 11(1): 45-46.
[31] Haase AA , Bauer EB, Kühn FE. et al.  Speciation and toxicity of rhenium salts, organometallics and coordination complexes[J]. Coord Chem Rev, 2019, 394: 135-161.   doi: 10.1016/j.ccr.2019.05.012
[32] Leondi AH, Souvatzoglou MA, Rapti AS, et al.  Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer[J]. Q J Nucl Med Mol Imaging, 2004, 48(3): 211-219.
[33] Minutoli F, Herberg A, Spadaro P, et al.  [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast[J]. Q J Nucl Med Mol Imaging, 2006, 50(4): 355-362.
[34] Küçük NÖ, İbiş E, Aras G, et al.  Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases[J]. Ann Nucl Med, 2000, 14(4): 239-245.   doi: 10.1007/bf02988205
[35] 孙燕, 管忠震, 廖美琳, 等.  肺癌骨转移诊疗专家共识(2014版)[J]. 中国肺癌杂志, 2014, 17(2): 57-72.   doi: 10.3779/j.issn.1009-3419.2014.02.01
Sun Y, Guan ZZ, Liao ML, et al.  Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 version)[J]. Chin J Lung Cancer, 2014, 17(2): 57-72.   doi: 10.3779/j.issn.1009-3419.2014.02.01